1307314-07-3Relevant articles and documents
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7′-thieno[2,3- C ]pyran) scaffold
Toledo, Miguel A.,Pedregal, Concepción,Lafuente, Celia,Diaz, Nuria,Martinez-Grau, Maria Angeles,Jiménez, Alma,Benito, Ana,Torrado, Alicia,Mateos, Carlos,Joshi, Elizabeth M.,Kahl, Steven D.,Rash, Karen S.,Mudra, Daniel R.,Barth, Vanessa N.,Shaw, David B.,McKinzie, David,Witkin, Jeffrey M.,Statnick, Michael A.
supporting information, p. 3418 - 3429 (2014/05/20)
Nociceptin/OFQ (N/OFQ) is a 17 amino acid peptide that is the endogenous ligand for the ORL1/NOP receptor. Nociceptin appears to regulate a host of physiological functions such as biological reactions to stress, anxiety, mood, and drug abuse, in addition
SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
-
Page/Page column 27, (2011/06/16)
An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.